好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterizing a Language Phenotype of Dementia with Lewy Bodies: A Clinicopathological Series
Aging, Dementia, and Behavioral Neurology
P13 - Poster Session 13 (8:00 AM-9:00 AM)
7-009

We report on three individuals with semantic variant primary progressive aphasia (svPPA) whose post-mortem pathology was consistent with diffuse neocortical Lewy body disease (LBD). We believe this is a heretofore unrecognized phenotype of LBD.

The present conception of primary dementias pairs clinical syndromes with neuropathologies, proven on necropsy or indirectly implicated by biomarkers. Each pairing is a clinicopathological entity. There is an increasing focus in the field of neurodegenerative disease to better characterize clinicopathological disorders, so as to target research and treatment approaches. SvPPA clinically manifests with progressive loss of semantic knowledge and is commonly associated with TDP-43 type C proteinopathy as well as Alzheimer's(AD) and other tau pathologies. We report on three instances of svPPA associated with LBD pathology. We believe this is the first such report in the literature.

Our institution's brain bank was queried for clinicopathological cases with a clinical diagnosis of svPPA and neuropathologic diagnosis of LBD. Three cases met the international consensus criteria for svPPA and were included in this study.

Three males aged 60-76 satisfied our inclusion criteria. Two subjects had significant temporal atrophy, and one had substantia nigral pallor. DAT scan was available in one subject, which was a negative study. All subjects fit the neuropathological consensus criteria for LBD with a diffuse neocortical distribution. In addition, all subjects had moderate vascular pathology and AD pathology (2-high ADNC, 1-intermediate). One case was also found with limbic associated Stage 1 TDP-43 proteinopathy.

Here we propose a novel language variant of Lewy body disease. Although rare, LBD should be included as a differential diagnosis in individuals with svPPA. In the future, characterizing phenotypes of LBD will assist in more precise targeting of research and treatment strategies.

Authors/Disclosures
Camille Merhi, MD (Texas A&M University)
PRESENTER
Dr. Merhi has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
M. Samy Abdullah, MD Dr. Abdullah has nothing to disclose.
Arash Salardini, MBBS (UTHSCA) Dr. Salardini has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. The institution of Dr. Salardini has received research support from NIH/NIA. The institution of Dr. Salardini has received research support from Taylor Family. Dr. Salardini has received publishing royalties from a publication relating to health care.
James F. Rini, MD (Ochsner Medical Center) Dr. Rini has a non-compensated relationship as a Member on Advisory Board with Lilly that is relevant to AAN interests or activities. Dr. Rini has a non-compensated relationship as a Member on Advisory Board with CND Lifesciences that is relevant to AAN interests or activities.
Alicia S. Parker, MD (UT Health San Antonio) An immediate family member of Dr. Parker has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Sanara Med Tech. An immediate family member of Dr. Parker has stock in Sanara Med Tech. An immediate family member of Dr. Parker has stock in Rochal Industries. An immediate family member of Dr. Parker has stock in Rochal Parnters. The institution of Dr. Parker has received research support from Texas Alzheimer's Research and Care Consortium. The institution of an immediate family member of Dr. Parker has received research support from Rochal Industries. An immediate family member of Dr. Parker has received intellectual property interests from a discovery or technology relating to health care.